論文・技術情報追加のお知らせ

1. Association of non-steroidal anti-inflammatory drug use with encephalopathy development: An analysis using the United States Food and Drug Administration Adverse Event Reporting System (FAERS) and Japanese Adverse Drug Event Report (JADER) databases.

ロキソプロフェンとエトドラクはウイルス性脳症と関連する可能性

対象DB：FAERS,JADER

2. Immune checkpoint inhibitors-associated diabetes and ketoacidosis were found in FAERS: A Real-World Evidence Database Study.

ICIsに関連する糖尿病とケトアシドーシスのリスクと特徴をFAERSで検討

対象DB：FAERS

3. Postmarketing Reports of Incomplete Dosing-Related Complications with Self-Injected PCSK9 Inhibitors: A Descriptive Study and Disproportionality Analysis.

自己注射型PCSK9阻害剤の投与失敗に関する後発市場での報告をFAERSで分析

対象DB：FAERS

4. A real-world pharmacovigilance analysis for transthyretin inhibitors: findings from the FDA adverse event reporting database.

FAERSを用いた3つのTTR阻害剤の安全性の比較研究

対象DB：FAERS

5. Analysis of post-market adverse events of tafamidis base on the FDA adverse event reporting system.

タファミジスに関連する有害事象の潜在的なリスクが特定

対象DB：FAERS

6. Anti-seizure medications-associated bladder and urethral symptoms: a pharmacovigilance analysis based on the FAERS database.

ASMsと膀胱および尿道症状の関連の研究

対象DB：FAERS

7. Efficacy of Prednisone Avoidance in Patients With Liver Transplant Using the U.S. Food and Drug Administration Adverse Event Reporting System.

肝移植患者において、プレドニゾン回避の有効性が明らかに

対象DB：FAERS

8. Cardiovascular Adverse Events Associated with Tumor Necrosis Factor-Alpha Inhibitors: A Real-World Pharmacovigilance Analysis.

TNFα阻害剤のうち、アダリムマブのみが心血管有害事象と関連

対象DB：FAERS

9. Comparison of the safety profiles for pirfenidone and nintedanib: a disproportionality analysis of the US food and drug administration adverse event reporting system.

PFDとNDNの副作用報告には差異があり、特にNDNでは心疾患と肝障害に注意

対象DB：FAERS

10. Pancreatitis with use of new diabetic medications: a real-world data study using the post-marketing FDA adverse event reporting system (FAERS) database.

DPP-4阻害剤とGLP-1作動薬は膵炎リスクが高い

対象DB：FAERS

11. Cardiotoxic profiles of CAR-T therapy and bispecific T-cell engagers in hematological cancers.

チサゲンレクロイセルは重篤な心障害を引き起こし、致死率が高い可能性

対象DB：VigiBase

12. A real-world pharmacovigilance study on cardiovascular adverse events of tisagenlecleucel using machine learning approach.

チサゲンレクロイセル治療で心血管有害事象の安全性シグナルを検知

対象DB：VigiBase

13. Impact of the Coronavirus Disease 2019 (COVID-19) Pandemic on the Severity and the Mortality of Acute Myocardial Infarction in Japan - Analysis From the JROAD-DPC Database.

COVID-19流行期に心原性ショックのAMI患者が増加

対象DB：DPC

14. Prescription patterns of psychotropics for adults treated with ADHD medications: Analysis of the National Database of Health Insurance Claims and Specific Health Checkups of Japan (NDB) of 2019.

2019年日本のADHD成人患者の向精神薬処方パターン分析

対象DB：NDB

15. Prevalence and clinical characteristics of people with HIV with limited treatment options in Japan: A Japanese claims data analysis.

HIV患者の3.6%が治療選択肢の制限を経験している

対象DB：MDV

16. A descriptive analysis of real-world oncology biosimilar use in Japan.

日本でバイオシミラー使用が増加し、抗腫瘍療法と併用されている

対象DB：MDV

17. Urate-lowering therapy in patients with hyperuricemia and heart failure: A retrospective cohort study using the UK Clinical Practice Research Datalink.

尿酸低下療法は心不全患者の入院・死亡リスクを低減

対象DB：CPRD

18. Mental health conditions and COVID-19 vaccine outcomes: A scoping review.

精神健康状態がCOVID-19ワクチンの接種意向や接種率に影響する可能性

対象DB：CPRD,THIN